Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients

Experimental Hematology

Volumn 36, Issue 12, 2008, Pages 1616-1624

  Sloand, Elaine M ^a   Pfannes, Loretta ^a   Scheinberg, Phillip ^a   More, Kenneth ^b   Wu, Colin O ^a   Horne, McDonald ^c   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL; LACTATE DEHYDROGENASE; PLASMIN; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOCYTE RELEASE REACTION; THROMBOSIS;

BLOOD CELLS; FEMALE; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYSIS; HUMANS; MALE; MEMBRANE PROTEINS; MUTATION; PLASMIN; PROTEIN TRANSPORT; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SOLUBILITY; THROMBOSIS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 55549137683     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.06.016     Document Type: Article

References (38)

1. Young N.S. Paroxysmal nocturnal hemoglobinuria: current issues in pathophysiology and treatment. Curr Hematol Rep 4 (2005) 103-109
2. Parker C., Omine M., Richards S., et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106 (2005) 3699-3709
3. Araten D.J., and Luzzatto L. The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 108 (2006) 734-736
4. Nishimura J., Kanakura Y., Ware R.E., et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 83 (2004) 193-207
5. Babiker A.A., Ronquist G., Nilsson U.R., and Nilsson B. Transfer of prostasomal CD59 to CD59-deficient red blood cells results in protection against complement-mediated hemolysis. Am J Reprod Immunol 47 (2002) 183-192
6. Brooimans R.A., van Wieringen P.A.M., Van Es L.A., and Daha M.R. Relative roles of decay-accelerating factor membrane cofactor protein and CD59 in the protection of human endothelial cells against complement-mediated lysis. Eur J Immunol 22 (1992) 3135-3140
7. Meri S., Morgan B.P., Davies A., Daniels R.H., Olavesen M.G., Waldmann H., and Lachmann P.J. Human protectin (CD59), an 18,000-2000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71 (1990) 1-9
8. Sloand E.M., and Young N.S. Thrombotic Complications in PNH. In: Young N.S., and Moss J. (Eds). PNH and the GPI-Linked Proteins (2000), Academic Press, San Diego, CA 101-112
9. Poskitt T.R., Fortwengler Jr. H.P., and Lunskis B.J. Activation of the alternate complement pathway by autologous red cel stroma. J Exp Med 138 (1973) 715-722
10. Simak J., Holada K., Risitano A.M., Zivny J.H., Young N.S., and Vstal J.G. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol 125 (2004) 804-813
11. Hugel B., Socie G., Vu T., et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 93 (1999) 3451-3456
12. Grunewald M., Siegemund A., Grunewald A., et al. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size. Blood Coagul Fibrinolysis 14 (2003) 685-695
13. Plesner T., Behrendt N., and Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 15 (1997) 398-408
14. Ploug M., Eriksen J., Plesner T., Hansen N.E., and Dano K. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem 208 (1992) 397-404
15. Plesner T., Ploug M., Ellis V., et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 83 (1994) 808-815
16. Moller L.B. Structure and function of the urokinase receptor. Blood Coagul. Fibrinolysis 4 (1993) 293-303
17. Ronne E., Pappot H., Grondahl-Hansen J., et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 89 (1995) 576-581
18. Ninomiya H., Hasegawa Y., Nagasawa T., and Abe T. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity. Int J Hematol 65 (1997) 285-291
19. Jo M., Thomas K.S., Wu L., and Gonias S.L. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem 278 (2003) 46692-46698
20. Bugge T.H., Flick M.J., Danton M.J., et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A 93 (1996) 5899-5904
21. Higazi A.A., Bdeir K., Hiss E., et al. Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. Blood 92 (1998) 2075-2083
22. Liebman H.A., and Feinstein D.I. Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res. 111 (2003) 235-238
23. Ellis V. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase. J Biol Chem 271 (1996) 14779-14784
24. Ellis V., Scully M.F., and Kakkar V.V. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 264 (1999) 2185-2188
25. Maciejewski J.P., Rivera C., Kook H., Dunn D., and Young N.S. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol 115 (2001) 1015-1022
26. Selleri C., Montuori N., Ricci P., et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 105 (2005) 2198-2205
27. Horne III M.K., Goad J.L., Merryman P.K., and Cullinane A.M. Comparison of the effect of histidine-rich glycoprotein and 6-aminohexanoic acid on plasmin production and fibrinolysis in vitro. Thromb Res 99 (2000) 179-186
28. Sloand E.M., Young N.S., Sato T., Kumar P., Kim S., Weichold F.F., and Maciejewski J.P. Secondary colony formation after long-term bone marrow culture using peripheral blood and bone marrow of HIV-infected patients. AIDS 11 (1997) 1547-1553
29. Sloand E., Young N.S., Sato T., Kim S., and Maciejewski J.P. Inhibition of interleukin-1β-converting enzyme in human hematopoietic progenitor cells results in blockade of cytokine-mediated apoptosis and expansion of their proliferative potential. Exp Hematol 26 (1998) 1093-1099
30. Hillmen P., Lewis S.M., Bessler M., Luzzatto L., and Dacie J.V. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 333 (1995) 1253-1258
31. Socié G., Mary J.Y., de Gramont A., et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 348 (1996) 573-577
32. Behrendt N., and Dano K. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system. FEBS Lett 393 (1996) 31-36
33. Hoyer-Hansen G., Pessara U., Holm A., et al. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J 358 (2001) 673-679
34. Higazi A.A., Upson R.H., Cohen R.L., et al. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood 88 (1996) 542-551
35. Tefs K., Gueorguieva M., Klammt J., et al. Molecular and clinical spectrum of type I plasminogen deficiency: a series of 50 patients. Blood 108 (2006) 3021-3026
36. Hall C., Richards S., and Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 102 (2003) 3587-3591
37. Devine D.V. The effects of complement activation on platelets. Curr Top Microbiol Immunol 178 (1992) 101-113
38. Hillmen P., Muus P., Duhrsen U., et al. The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Blood 108 (2007) 23 Abstract